NasdaqGS:ALNYBiotechs
Alnylam (ALNY) Stock May Look Rich On Earnings Despite Weaker Price Action
Alnylam Pharmaceuticals has had a difficult run over the past year, with the share price down 46.8%, while the current valuation checks still lean toward the stock being on the expensive side rather than a clear bargain.
Over the past 12 months, Alnylam Pharmaceuticals shareholders have seen the stock decline 46.8%, which puts a spotlight on whether earlier optimism was too strong.
Upcoming clinical data on RNAi programs like the transthyretin and hypertension studies can support sentiment...